Cargando…

Peripheral neuropathy in persons with tuberculosis

Peripheral neuropathy (PN) is a serious condition affecting the nerves that is commonly seen in patients with tuberculosis (TB). Causes of PN in patients with TB are multiple, and can include TB itself, other co-morbid conditions, such as Human Immune-deficiency virus (HIV) disease, malnutrition, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Mafukidze, Arnold T, Calnan, Marianne, Furin, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852705/
https://www.ncbi.nlm.nih.gov/pubmed/31768422
http://dx.doi.org/10.1016/j.jctube.2015.11.002
_version_ 1783469895130808320
author Mafukidze, Arnold T
Calnan, Marianne
Furin, Jennifer
author_facet Mafukidze, Arnold T
Calnan, Marianne
Furin, Jennifer
author_sort Mafukidze, Arnold T
collection PubMed
description Peripheral neuropathy (PN) is a serious condition affecting the nerves that is commonly seen in patients with tuberculosis (TB). Causes of PN in patients with TB are multiple, and can include TB itself, other co-morbid conditions, such as Human Immune-deficiency virus (HIV) disease, malnutrition, or diabetes mellitus (DM), and several anti-tuberculous medications. The condition can manifest with a variety of symptoms, and a diagnosis can usually be made on a clinical basis. Treatment and prognosis of PN vary depending on the underlying cause, but often the condition can lead to permanent disability in individuals with TB. For this reason, primary prevention is key as is early identification and management of symptoms. Treatment can include withdrawal of possible offending agents, vitamin supplementation, physical therapy, analgesics, and targeted agents, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and gabapentin. Additional research is needed to better describe the morbidity and disability associated with PN in persons with TB and to improve management strategies for persons at risk for and affected by this condition. Case review: RM is a 47 year-old man who is in his third month of treatment for drug-resistant TB (DR-TB). His treatment regimen consists of kanamycin (1 gm intramuscular daily), levofloxacin (1000 mg by mouth daily), cycloserine (750 mg by mouth daily), ethionamide (750 mg by mouth daily), pyrazinamide (1500 mg by mouth daily), and Para-Amino Salicylate (12 gm by mouth daily). He is HIV-infected with a CD4 count of 470 cell/µl and on a stable antiretroviral therapy regimen of tenofovir, lamivudine, and efavirenz, which he started 8 weeks ago. He works in a platinum mine, denies smoking, reports drinking beer “on the weekend” and denies other drugs. He presents for his 3 month clinical visit for his DR-TB follow-up and states he is doing well, but he does report some “burning” in the bottom of his feet.
format Online
Article
Text
id pubmed-6852705
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68527052019-11-25 Peripheral neuropathy in persons with tuberculosis Mafukidze, Arnold T Calnan, Marianne Furin, Jennifer J Clin Tuberc Other Mycobact Dis Article Peripheral neuropathy (PN) is a serious condition affecting the nerves that is commonly seen in patients with tuberculosis (TB). Causes of PN in patients with TB are multiple, and can include TB itself, other co-morbid conditions, such as Human Immune-deficiency virus (HIV) disease, malnutrition, or diabetes mellitus (DM), and several anti-tuberculous medications. The condition can manifest with a variety of symptoms, and a diagnosis can usually be made on a clinical basis. Treatment and prognosis of PN vary depending on the underlying cause, but often the condition can lead to permanent disability in individuals with TB. For this reason, primary prevention is key as is early identification and management of symptoms. Treatment can include withdrawal of possible offending agents, vitamin supplementation, physical therapy, analgesics, and targeted agents, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and gabapentin. Additional research is needed to better describe the morbidity and disability associated with PN in persons with TB and to improve management strategies for persons at risk for and affected by this condition. Case review: RM is a 47 year-old man who is in his third month of treatment for drug-resistant TB (DR-TB). His treatment regimen consists of kanamycin (1 gm intramuscular daily), levofloxacin (1000 mg by mouth daily), cycloserine (750 mg by mouth daily), ethionamide (750 mg by mouth daily), pyrazinamide (1500 mg by mouth daily), and Para-Amino Salicylate (12 gm by mouth daily). He is HIV-infected with a CD4 count of 470 cell/µl and on a stable antiretroviral therapy regimen of tenofovir, lamivudine, and efavirenz, which he started 8 weeks ago. He works in a platinum mine, denies smoking, reports drinking beer “on the weekend” and denies other drugs. He presents for his 3 month clinical visit for his DR-TB follow-up and states he is doing well, but he does report some “burning” in the bottom of his feet. Elsevier 2015-12-03 /pmc/articles/PMC6852705/ /pubmed/31768422 http://dx.doi.org/10.1016/j.jctube.2015.11.002 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Mafukidze, Arnold T
Calnan, Marianne
Furin, Jennifer
Peripheral neuropathy in persons with tuberculosis
title Peripheral neuropathy in persons with tuberculosis
title_full Peripheral neuropathy in persons with tuberculosis
title_fullStr Peripheral neuropathy in persons with tuberculosis
title_full_unstemmed Peripheral neuropathy in persons with tuberculosis
title_short Peripheral neuropathy in persons with tuberculosis
title_sort peripheral neuropathy in persons with tuberculosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852705/
https://www.ncbi.nlm.nih.gov/pubmed/31768422
http://dx.doi.org/10.1016/j.jctube.2015.11.002
work_keys_str_mv AT mafukidzearnoldt peripheralneuropathyinpersonswithtuberculosis
AT calnanmarianne peripheralneuropathyinpersonswithtuberculosis
AT furinjennifer peripheralneuropathyinpersonswithtuberculosis